Trademarkia Logo

Canada

C$
CENTESSA
REGISTERED

on 11 Apr 2024

Last Applicant/ Owned by

CENTESSA PHARMACEUTICALS PLC

3rd Floor 1 Ashley Road, Altrincham, Cheshire WA14 2DT

GB

Serial Number

2143268 filed on 30th Jul 2021

Registration Number

TMA1228847 registered on 11th Apr 2024

Registration expiry Date

30th Jul 2031

Correspondent Address

GOWLING WLG (CANADA) LLP

SUITE 16001 FIRST CANADIAN PLACE100 KING STREET WESTTORONTO

ONTARIO

CA

M5X1G5

CENTESSA

Trademark usage description

pharmaceutical products, preparations and medicines for the treatment and prevention of hemophilia, tumors, hypertension, narcolepsy, autoimmune disea Read More

Classification Information


Class [005]
Pharmaceutical products, preparations and medicines for the treatment and prevention of hemophilia, tumors, hypertension, narcolepsy, autoimmune diseases and disorders, respiratory diseases and disorders, cardiovascular diseases and disorders, central nervous system diseases and disorders, cancer, intractable diseases of liver, lung and heart; pharmaceutical products, preparations and medicines for the treatment and prevention of endocrinology diseases and disorders, namely diabetes, thyroid diseases, Addison's disease, and Cushing's disease; anti-inflammatory medications; anti-fibrotic pharmaceutical preparations; pharmaceutical preparations to treat cancer, intractable diseases of liver, lung and heart; food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; preparations for destroying vermin; fungicides, herbicides.


Classification kind code

11

Class [010]
Medical devices, namely implantable drug delivery devices and nasal spray drug delivery devices; surgical instruments; artificial limbs, eyes and teeth; suture materials;


Classification kind code

11

Class [042]
Research in the medical and pharmaceutical field; pharmaceutical research services; pharmaceutical drug development services; research and development in the pharmaceutical and pharmaceutical biotechnology fields; medical laboratories; scientific and technological services, namely, drug discovery services; research in the field of drug discovery; design and development of computer hardware and software; pharmaceutical research and development.


Classification kind code

11

Class [044]
Medical services, namely, providing medical therapies for hemophilia; medical services, namely, administration of pharmaceutical treatments for pulmonary arterial hypertension, oncological and autoimmune diseases; medical services, namely, providing medical treatments for narcolepsy; medical services, namely, providing medical treatments for skin disorders; providing medical information, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; pharmaceutical information services; pharmaceutical consultation and counseling; medical consultation and counseling in the fields of hemophilia, pulmonary arterial hypertension, oncological and autoimmune diseases, narcolepsy, and skin disorders; treatments for orphan diseases of the kidney, including ADPKD; therapies for hemophilia; pharmaceutical treatments for pulmonary arterial hypertension, oncological and autoimmune diseases; treatments for narcolepsy; and treatments for skin disorders; veterinary services; aquaculture, horticulture services


Classification kind code

11

Mark Details


Serial Number

2143268

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 22
on 17th Feb 2023
Search Recorded
Submitted for opposition 20
on 17th Feb 2023
Examiner's First Report
Submitted for opposition 256
on 29th Aug 2022
Notification of Possible Opposition Sent
Submitted for opposition 257
on 11th Nov 2021
Designation Notification - Madrid Protocol
Submitted for opposition 257
on 28th Oct 2021
Designation Notification - Madrid Protocol
Submitted for opposition 31
on 27th Oct 2021
Formalized
Submitted for opposition 1
on 27th Oct 2021
Created
Submitted for opposition 228
on 30th Jul 2021
International Registration
Submitted for opposition 210
on 30th Jul 2021
IR Correction
Submitted for opposition 30
on 30th Jul 2021
Filed